Stability of New Carbapenem DA-1131 to Renal Dipeptidase (Dehydropeptidase I)-Reference-Cited by-同舟云学术

Stability of New Carbapenem DA-1131 to Renal Dipeptidase (Dehydropeptidase I)

Published:2002-02 Issue:2 Volume:46 Page:575-577
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Park Sung Wook¹,We Jeoung Soon¹,Kim Gye Won²,Choi Seong Hak²,Park Haeng Soon¹

Affiliation:

1. Department of Pharmacy, College of Pharmacy, Chonnam National University, Kwangju

2. and Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Kyunggi-Do, Korea

Abstract

ABSTRACT The stability of DA-1131 to renal dipeptidase (RDPase) (EC 3.4.13.19) was compared with that of imipenem and meropenem by V max / K m ratios as an index of the enzyme's preference for substrates. Our results showed a decreasing order of imipenem (6.24), meropenem (2.41), and DA-1131 (1.39). The biochemical evaluation of DA-1131 as the least preferred substrate of RDPase suggests its potential use as a novel β-lactam antibiotic which may be usable without coadministration of RDPase inhibitors once its clinical suitability is proven.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.2.575-577.2002

Reference24 articles.

1. Blumer, J. L. 1997. Meropenem: evaluation of a new generation carbapenem. Int. J. Microb. Agents8:73-92.

2. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

3. Campbell, B. J., Y. D. Shih, L. J. Forrester, and W. L. Zahler. 1988. Specificity and inhibition studies of human renal dipeptidase. Biochim. Biophys. Acta956:110-118.

4. Edwards, J. R., P. J. Turner, C. Wannop, E. S. Withnell, A. J. Grindey, and K. Nairn. 1989. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob. Agents Chemother.33:215-222.

5. Fukasawa, M., Y. Sumita, E. T. Harabe, T. Tanio, H. Nouda, T. Kohzuke, T. Okuda, H. Matsumura, and M. Sunagawa. 1992. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother.36:1577-1579.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Two-Step Infusion Improve the Pharmacokinetics/Pharmacodynamics Target Attainment of Meropenem in Critically Ill Patients?;Journal of Pharmaceutical Sciences;2024-09

2. Physiologically based pharmacokinetic modeling to predict OAT3-mediated drug-drug interactions of meropenem in varying stages of chronic kidney disease;European Journal of Pharmaceutical Sciences;2023-04

3. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals;Frontiers in Pharmacology;2023-03-07

4. Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling;Clinical Pharmacokinetics;2022-08-10

5. A Review on Meropenem;Research Journal of Pharmacy and Technology;2021-09-14